GlaxoSmithKline
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
Bioequivalence Study of Montelukast 10 mg Tablets
- First Posted Date
- 2013-09-17
- Last Posted Date
- 2017-06-15
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 32
- Registration Number
- NCT01943942
A Phase IIa Study of the MEK Inhibitor Trametinib Monotherapy in the Treatment of Biliary Tract Cancers
- Conditions
- Cancer
- Interventions
- First Posted Date
- 2013-09-17
- Last Posted Date
- 2017-05-31
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 20
- Registration Number
- NCT01943864
- Locations
- 🇯🇵
GSK Investigational Site, Tokyo, Japan
Study to Evaluate the Safety, Tolerability and Pharmacokinetic of Single and 14 Day Repeat Topical Application of GSK1940029
- Conditions
- Acne Vulgaris
- Interventions
- Drug: 0.3% GSK1940029 gelDrug: 1% GSK1940029 gelDrug: 0.3%/1% vehicle gel only
- First Posted Date
- 2013-09-10
- Last Posted Date
- 2017-05-09
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 55
- Registration Number
- NCT01938482
- Locations
- 🇦🇺
GSK Investigational Site, Adelaide, South Australia, Australia
Minocycline Bioequivalence Study
- First Posted Date
- 2013-09-10
- Last Posted Date
- 2013-11-18
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 28
- Registration Number
- NCT01938508
- Locations
- 🇲🇽
GSK Investigational Site, Mexico City, Mexico
Safety and Tolerability of Trametinib in Combination With Docetaxel in Japanese Subjects With Non-small Cell Lung Cancer
- Conditions
- Lung Cancer, Non-Small Cell
- Interventions
- First Posted Date
- 2013-09-10
- Last Posted Date
- 2014-07-28
- Lead Sponsor
- GlaxoSmithKline
- Registration Number
- NCT01938456
A Dose Escalation Study to Assess Safety of GSK2256098 (FAK Inhibitor) in Combination With Trametinib (MEK Inhibitor) in Subjects With Advanced Solid Tumors
- First Posted Date
- 2013-09-10
- Last Posted Date
- 2019-07-12
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 34
- Registration Number
- NCT01938443
- Locations
- 🇬🇧
GSK Investigational Site, Newcastle upon Tyne, United Kingdom
REMS Retigabine Study
- Conditions
- Epilepsy
- Interventions
- Other: Survey Responses
- First Posted Date
- 2013-09-10
- Last Posted Date
- 2014-10-01
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1
- Registration Number
- NCT01938560
To Evaluate Plasma and Pulmonary Pharmacokinetics of GSK2140944
- Conditions
- Infections, Bacterial
- Interventions
- Drug: GSK2140944 (Single dose)Drug: GSK2140944 (Multiple dose)
- First Posted Date
- 2013-09-04
- Last Posted Date
- 2017-05-15
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 22
- Registration Number
- NCT01934205
- Locations
- 🇺🇸
GSK Investigational Site, Baltimore, Maryland, United States
Characterization of Exposure From Topical Administration of [14C] Umeclidinium to Axilla or Palm of Healthy Male Subjects
- Conditions
- Hyperhidrosis
- Interventions
- Drug: [14C]Umeclidinium 18.5 mg
- First Posted Date
- 2013-09-04
- Last Posted Date
- 2017-05-15
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 18
- Registration Number
- NCT01934153
- Locations
- 🇳🇱
GSK Investigational Site, Zuidlaren, Netherlands
Immunogenicity and Safety Study of Different Formulations of GlaxoSmithKline (GSK) Biologicals H7N1 Influenza Vaccine Administered to Adults 21 to 64 Years of Age
- Conditions
- Influenza
- Interventions
- Biological: Investigational H7N1 vaccine GSK2789869ABiological: Investigational H7N1 vaccine GSK2789868ABiological: Placebo
- First Posted Date
- 2013-09-04
- Last Posted Date
- 2017-05-08
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 427
- Registration Number
- NCT01934127
- Locations
- 🇨🇦
GSK Investigational Site, Toronto, Ontario, Canada